WO2003018047A3 - Hdl for the treatment of stroke and other ischemic conditions - Google Patents

Hdl for the treatment of stroke and other ischemic conditions Download PDF

Info

Publication number
WO2003018047A3
WO2003018047A3 PCT/EP2002/009294 EP0209294W WO03018047A3 WO 2003018047 A3 WO2003018047 A3 WO 2003018047A3 EP 0209294 W EP0209294 W EP 0209294W WO 03018047 A3 WO03018047 A3 WO 03018047A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdl
stroke
treatment
ischemic conditions
ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009294
Other languages
French (fr)
Other versions
WO2003018047A2 (en
Inventor
Alphonse Hubsch
Markus G Lang
Peter G Lerch
Roberto Paterno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
ZLB Bioplasma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Priority to JP2003522564A priority Critical patent/JP4284177B2/en
Application filed by ZLB Bioplasma AG filed Critical ZLB Bioplasma AG
Priority to ES02774525T priority patent/ES2304452T3/en
Priority to CA2457840A priority patent/CA2457840C/en
Priority to EP02774525A priority patent/EP1425031B8/en
Priority to HK04107205.2A priority patent/HK1064304B/en
Priority to DE60226881T priority patent/DE60226881D1/en
Priority to AU2002340825A priority patent/AU2002340825B2/en
Priority to US10/487,224 priority patent/US20040266660A1/en
Publication of WO2003018047A2 publication Critical patent/WO2003018047A2/en
Publication of WO2003018047A3 publication Critical patent/WO2003018047A3/en
Priority to ZA2004/01360A priority patent/ZA200401360B/en
Anticipated expiration legal-status Critical
Priority to US11/744,780 priority patent/US7491693B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method for the prophylaxis and/or treatment of stroke and other ischemic injury, wherein HDL is administered to a subject in need thereof, particularly by intravenous infusion.
PCT/EP2002/009294 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions Ceased WO2003018047A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2002340825A AU2002340825B2 (en) 2001-08-20 2002-08-20 HDL for the treatment of stroke and other ischemic conditions
DE60226881T DE60226881D1 (en) 2001-08-20 2002-08-20 HIGH-DENSITY LIPOPROTEIN FOR THE TREATMENT OF IMPACT AND ISCHEMIA STATE
ES02774525T ES2304452T3 (en) 2001-08-20 2002-08-20 AN HDL FOR THE TREATMENT OF AN ICTUS AND OTHER ISCHEMICAL CONDITIONS.
CA2457840A CA2457840C (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
EP02774525A EP1425031B8 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
HK04107205.2A HK1064304B (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
US10/487,224 US20040266660A1 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
JP2003522564A JP4284177B2 (en) 2001-08-20 2002-08-20 HDL for the treatment of stroke and other ischemic conditions
ZA2004/01360A ZA200401360B (en) 2001-08-20 2004-02-19 Hdl for the treatment of stroke and other ischemic conditions
US11/744,780 US7491693B2 (en) 2001-08-20 2007-05-04 HDL for the treatment of stroke and other ischemic conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
EP01120026.8 2001-08-20
US60/313,605 2001-08-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10487224 A-371-Of-International 2002-08-20
US11/744,780 Continuation US7491693B2 (en) 2001-08-20 2007-05-04 HDL for the treatment of stroke and other ischemic conditions

Publications (2)

Publication Number Publication Date
WO2003018047A2 WO2003018047A2 (en) 2003-03-06
WO2003018047A3 true WO2003018047A3 (en) 2004-01-29

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009294 Ceased WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Country Status (10)

Country Link
US (2) US20040266660A1 (en)
EP (1) EP1425031B8 (en)
JP (1) JP4284177B2 (en)
AT (1) ATE396736T1 (en)
AU (1) AU2002340825B2 (en)
CA (1) CA2457840C (en)
DE (1) DE60226881D1 (en)
ES (1) ES2304452T3 (en)
WO (1) WO2003018047A2 (en)
ZA (1) ZA200401360B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (en) * 2005-06-28 2007-01-04 Osaka University Pharmaceutical composition comprising substance capable of inhibiting or promoting progranulin activity and screening method for substance capable of inhibiting or promoting progranulin activity
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
JP5601750B2 (en) * 2007-03-01 2014-10-08 シーエスエル、リミテッド Treatment of abnormal endothelial function in diabetic patients
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
CN102802618B (en) 2009-06-25 2014-06-18 泰特拉有限公司 Therapeutic combinations of nicotinic acid and meldonium
EP2676659A1 (en) 2009-07-16 2013-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) HDL comprising a therapeutic agent and use in therapy
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
WO2012103163A2 (en) * 2011-01-25 2012-08-02 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
KR20140036167A (en) * 2011-03-25 2014-03-25 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 Pegylated human hdl particle and process for production thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Apomers
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022076324A1 (en) * 2020-10-05 2022-04-14 Northwestern University Targeted ph sensitive liposomes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
KR20240171131A (en) 2022-04-06 2024-12-06 아비오닉스 파마 에스에이 Method for treating leukocytosis, endothelial dysfunction and carditis using lipid-binding protein-based complexes
JP2025519606A (en) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー Methods for treating acute conditions using lipid-binding protein-based conjugates - Patents.com
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
CN121219001A (en) 2023-01-13 2025-12-26 阿比奥尼克斯制药公司 Lipid-binding protein molecular therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2026008645A1 (en) 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780592A (en) * 1995-12-20 1998-07-14 Hoechst Aktiengesellschaft Compositions comprising lipoproteins and crotonamide derivatives
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001013939A1 (en) * 1999-08-19 2001-03-01 Queen Mary And Westfield College High density lipoprotein against organ dysfunction following haemorrhagic shock

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780592A (en) * 1995-12-20 1998-07-14 Hoechst Aktiengesellschaft Compositions comprising lipoproteins and crotonamide derivatives
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001013939A1 (en) * 1999-08-19 2001-03-01 Queen Mary And Westfield College High density lipoprotein against organ dysfunction following haemorrhagic shock

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COCKERILL G. W. ET AL.: "HIGH-DENSITY LIPOPROTEINS RESCUE END-STAGE ORGAN FAILURE IN A RAT MODEL OF HAEMORRHAGIC SHOCK", JOURNAL OF SUBMICROSCOPIC CYTOLOGY AND PATHOLOGY, vol. 32, no. 3, 1 July 2000 (2000-07-01), pages 353, XP001073434 *
KLIMOV A N ET AL: "EFFECT OF HIGH DENSITY LIPOPROTEINS ON PERMEABILITY OF RABBIT AORTA TO LOW-DENSITY LIPOPROTEINS", ATHEROSCLEROSIS, vol. 55, no. 2, 1985, pages 217 - 224, XP001073581, ISSN: 0021-9150 *

Also Published As

Publication number Publication date
WO2003018047A2 (en) 2003-03-06
ZA200401360B (en) 2005-08-31
EP1425031A2 (en) 2004-06-09
EP1425031B1 (en) 2008-05-28
US20040266660A1 (en) 2004-12-30
JP2005501110A (en) 2005-01-13
DE60226881D1 (en) 2008-07-10
JP4284177B2 (en) 2009-06-24
ES2304452T3 (en) 2008-10-16
EP1425031B8 (en) 2008-09-03
CA2457840A1 (en) 2003-03-06
HK1064304A1 (en) 2005-01-28
US20080108550A1 (en) 2008-05-08
CA2457840C (en) 2011-10-11
ATE396736T1 (en) 2008-06-15
US7491693B2 (en) 2009-02-17
AU2002340825B2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2003018047A3 (en) Hdl for the treatment of stroke and other ischemic conditions
WO2002003911A8 (en) Prevention and treatment of alzheimer's disease
WO2002009699A3 (en) Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
EP2174662A3 (en) Methods for treating muscle injuries
WO2005063734A3 (en) Substituted thiophenes
DK1411932T3 (en) Combination therapy with substituted oxazolidinones
WO2002102394A3 (en) Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
WO2002036106A3 (en) Novel medicament compositions based on anticholinergics and corticosteroids
DK0665749T3 (en) Composition for the treatment of Parkinson's disease
WO2003020024A3 (en) Treatment and prevention of infections in plants
WO2002072005A3 (en) Linear y-carboxyglutamate rich conotoxins
WO2006072347A3 (en) Alkinyl-substituted thiophenes
WO2007031520A3 (en) Use of octenidine dihydrochloride in semisolid preparations
WO2004096268A3 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
WO2002007678A3 (en) Mu-conopeptides
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
WO2006072348A3 (en) Alkinyl-substituted thiophenes
WO2005025617A3 (en) Methods and compositions for treating herpes infections
HK1046367A1 (en) Treating allergic and inflammatory conditions
WO2005020887A3 (en) Method for treatment of severe acute respiratory syndrome
WO2005007600A3 (en) Novel methods using aminobenzoic acid compounds
WO2002022079A3 (en) Methods of preparing immune globulin and uses thereof
WO2005047278A3 (en) Substituted dihydroquinazolines ii
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2003024486A1 (en) Remedies for bone loss

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002340825

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002774525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2457840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003522564

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/01360

Country of ref document: ZA

Ref document number: 200401360

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002774525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10487224

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002340825

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2002774525

Country of ref document: EP